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We present a case report of a 75-years-old woman affected by renal clear cell carcinoma with a synchronous pancreatic metastasis
and a metachronous lung metastasis. This case has two peculiarities. First the pancreatic metastasis was treated just with medical
therapy, that is, Sunitinib, instead of the surgical therapy that is mostly considered. Secondly, the pancreatic lesion showed different
characteristics on the computed tomography scan compared to the usual pancreatic metastases from renal clear cell carcinoma.
The pancreatic metastasis totally regressed after medical treatment and nowadays, four years after the diagnosis, the patient is
disease-free.
1. Introduction
The presence of pancreatic metastases from solid tumours is
a rare event, with an incidence rate varying from 1.6% to 11%
in autopsy series of patients affected by advanced neoplasm
[1]. The neoplasms that could give these types of metastases
are melanoma, lung tumours, colic neoplasms, breast cancer,
and with a higher rate of frequency the kidney tumours
[2]. In many cases described in the literature pancreatic
metastases due to kidney carcinoma usually manifest many
years after the diagnosis of the primitive tumour [3–6].
Treatment usually is surgery, with satisfying results in terms
of overall survival and disease-free survival [2–4, 7].
2. Case Presentation
The patient, a 75-year-old female, had a positive oncological
anamnesis: her brother was affected by rectal neoplasm
and her three aunts were affected by breast cancer, bladder
cancer, and rectal cancer, respectively. The patient was under
medical treatment for hypertension and due to the onset
of general malaise, anemia, and asthenia, she performed a
total body contrast enhanced computed tomography (CECT)
scan. CECT total body scan was performed with a triphasic
study of the abdomen and with a urographic phase.The scans
showed the presence of an expansive solid growing mass
with multilobulated shapes on the left kidney. The lesion was
90mm (Longitudinal Diameter-LD) × 85mm (Transversal
Diameter-TD) × 96mm (Anteroposterior Diameter-APD)
sized (Figures 1(a), and 1(b)). The mass infiltrated the renal
pelvis and the mid calyx (Figure 1(c)); proximal ureter was
encased but not infiltrated (Figure 1(d)). The mass showed
an inhomogeneous enhancement after contrast medium
administration due to the presence of solid parts; many
colliquative-necrtotic areas and intralesional calcifications
were also found (Figures 2(a) and 2(b)). An enlargement
of the ipsilateral splenic vein, 9mm sized (Figure 2(c)),
and many intralesional collateral vessels were also observed
(Figure 2(d)). No radiological signs of thrombosis of themain
arteries or veins were detected. At the istm of the pancreas
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Figure 1: (a) and (b) show the presence of the renal lesion withmultilobulated shapes, in the left kidney, 90mm (LD) × 85mm (TD) × 96mm
(APD) in size. (c) and (d) show the extension and the location of the renal lesion, mass infiltrates the renal pelvis and the mid calyx (c), and
proximal ureter was encased but not infiltrated (d). Arrows indicate the lesion. (a) Axial CT scan, precontrast phase. (b) CECT, multiplanar
reconstruction (MPR) Coronal Plane. (c) CECT-MPR: Sagittal Plane. (d) Axial-CECT, urographic phase.
a nodular round-shaped lesion, 6mm in size, was observed.
The lesion, isodense in the precontrast scans (Figure 3(a)),
after contrast medium administration, appeared hypervascu-
larized in all the three phases of the study with a rich vascular
supply (Figures 3(b), 3(c), 3(d), and 3(e)) and was referable,
due to its contrastographic behavior, to a local metastasis or
to a primitive neuroendocrine tumor. The pancreatic lesion
showed on CECT scan unusual characteristics for a metasta-
sis from renal clear cell carcinoma and, before considering
surgical excision of the pancreatic mass, we decided that
biopsy of the pancreatic lesion was needed in order to assess
its nature. So the patient underwent a left nephrectomy with
surrenalectomy and at the same time biopsy of the pancreatic
lesion was performed. At the histological examination the
renal mass resulted to be a clear cell carcinoma and the
pancreatic lesion was found to be a metastasis of clear cell
renal carcinoma.
Despite the guidelines indicated a local excision of the
pancreatic lesion, we decided to start a systemic treatment,
considering that the patient was not able to perform a second
surgery because she had just undergone a major surgical
intervention and she was not in good clinical condition at
that time [8]. So, the patient started medical treatment with
Sunitinib, 50mg/day for two cycles. Due to the onset of
grade III skin toxicity and gastrointestinal toxicity, the dose of
Sunitinib was reduced to 37.5mg/day for other six cycles [9].
After three months of treatment another CECT total body
scan was performed. CECT scan showed in the posterior-
basal segment of the inferior right lobe, close to the pleural
wall, a solid nodular lesion, 10mm(LD)× 8mm(TD)× 8mm
(APD) sized (Figures 4(a) and 4(b)). The hypervascularized
pancreatic lesionwas notmore observed; a hypodense round-
shaped lesion in the same region was observed (Figures 4(c)
and 4(d)) which was a colliquative-necrotic outcome of the
therapy. Considering that the lung lesion appeared during
treatment with Sunitinib we thought that the best therapeutic
choice was to remove surgically the lung lesion, mainly for
two reasons.The first reason was that the patient was in good
general clinical condition with adequate lung function and
the lesion was surgically resectable. So, according to guide-
lines, surgery was indicated [8]. The second reason was that
the lung lesion appeared during treatment with Sunitinib,
while the pancreatic metastases disappeared, so there was
a possibility that the lung lesion was a second malignancy.
In our case we decide to surgically remove the lung lesion
in order to cure the patient and also because a histological
characterization of the lung lesion was needed in order
to differentiate the lung lesion from a second malignancy.
Therefore, the patient performed surgical removal of the lung
lesion. Histological examination deposed for metastasis from
clear cell renal carcinoma.
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Figure 2: Images show the contrastographic behavior of the renal lesion and its relations with the surrounding anatomical structures. The
lesion showed an inhomogeneous enhancement after contrast medium administration due to the presence of solid parts (a), and many
colliquative-necrotic areas and intralesional calcifications (b) were also seen. An enlargement of the ipsilateral splenic vein, 9mm sized,
(c) and many intralesional collateral vessels (d) were seen. (a) CECT-MPR-Sagittal Plane. (b) CECT-Arterial Phase-Axial. (c) CECT-Venous
phase-Axial. (d) CECT-Arterial phase-Axial.
After the surgery the patient performed two more cycles
of Sunitinib, stopped due to poor tolerance, a total of
eight cycles were administrated. The following CECT exams
showed the outcomes, such as metallic clips, of the left
nephrectomy and surrenalectomy (Figure 5(a)), and of the
resection of the lung metastasis (Figure 5(b)); no local
relapses were seen in both the organs. The previous hypo-
dense lesion seen at the istm of the pancreas totally regressed
and no other pancreatic lesions were observed (Figure 5(c)).
Nowadays the patient is under oncological follow-up; she is
in a good state of health, and she is disease-free for 47months
from the diagnosis of the tumour and for 20months from the
end of the treatment with Sunitinib.
3. Discussion
The presence of pancreatic metastases from solid tumours is
a rare event, with an incidence rate varying from 1.6% to 11%
in autopsy series of patients affected by advanced neoplasms
[1]. The neoplasms that could give this type of metastases are
melanoma, lung tumours, colic neoplasms, breast cancer, and
with a higher rate of frequency kidney tumours [2]. Metasta-
sization to the pancreas is most likely due to haematogenous
spreading and the site of the tumour, right or left kidney,
is an independent prognostic factor of metastasization. This
occurs, as described in the analysis of Sellner et al., for the
high affinity of the renal cancer cells for the parenchyma of
the pancreas [10]. In a review of the literature performed by
Sellner et al., diagnosis in only 35% of the cases was made
in asymptomatic patients. In the remaining 65% of cases,
the patients had various symptoms including the following:
abdominal pain (20%), gastrointestinal bleeding due to infil-
tration of the duodenum (20%), obstructive jaundice (9%),
weight loss (9%), pancreatitis, and diabetes (3%) [10]. Inmany
cases the metastases were metachronous with appearance
2–18 years after the diagnosis of the primary tumour [11].
The treatment of the metastases is usually surgical, with
good results in terms of overall survival (about 43 months)
and disease-free survival (23.6 months), while the 5-year
survival after surgery is between 43% and 88% [2, 4]. Usually
metastases from clear cell renal carcinoma on CT scan are
isoattenuating in the unenhanced phase, as observed in
our case. After contrast medium administration pancreatic
metastases from renal clear cell carcinoma usually closely
resemble the appearance of the primary carcinoma, showing
on CECT scan irregular and not well-rounded shapes, a
nonhomogenous and irregular contrast enhancement, and
a central hypoenhancing necrotic portion [12–14]. Despite
these general features, in our case the pancreatic metas-
tasis on CECT scan showed well-rounded shapes and a
homogenous and uniform contrast enhancementwithout any
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Figure 3: Images show the presence of a round-lesion at the pancreatic istm; the lesion hypodense in the precontrast study (a), appeared
hypervascularized in all the three phases of the exam ((b), (c), (d), and (e)). Circles indicate the lesion. (a) Precontrast-Axial. (b) CECT-
Arterial Phase-Axial. (c) CECT-Venous Phase-Axial. (d) CECT-Venous Phase. Coronal Plane. (e) CECT-Late Phase-Coronal Plane.
hypoenhnacing necrotic portion. According to the literature
and to our daily radiological experience small hypervascular
lesions, with rounded shapes and with a rich and uniform
contrast enhancement, as observed in our case, rarely could
be referred to metastases from renal clear cell carcinoma.
Most often small pancreatic lesions, with rounded shapes and
with a uniform contrast enhancement on CECT scan, could
be referred to neuroendocrine pancreatic tumours, primitive
or metastatic to the pancreas [12–14]. For these reasons the
pancreatic lesion observed in our case presented, on CECT
scan, unusual characteristics for a metastasis from renal clear
cell carcinoma and this is why the biopsy of the lesion was
performed.
In our case the diagnosis of the pancreatic metastasis
is synchronous to the primary tumour, unlike the majority
of the cases reported in the literature, where the metastases
appeared many years after the diagnosis of the primary
tumour. In our case the symptomatology was very mild and
nonspecific, not clearly indicative of the presence of a pan-
creatic lesion. Although the guidelines indicate the need for a
complete local excision, in our case the patient, who had just
performed a major abdominal surgery with nephrectomy,
was not in suitable clinical conditions to undergo a second
surgical procedure [8]. Thus, the type of treatment we have
chosen was pharmacological, using Sunitinib an inhibitor of
the tyrosine kinase receptor. Regarding the pulmonary mass,
because it appeared during the treatment with Sunitinib, we
had thought it was probably a selection of a clone of resistant
cells or a second malignancy, so, considering that the patient
at that time was in a good clinical condition to perform
another surgery, the best therapeutic choice was the surgical
resection in order to make a correct differential diagnosis
and to obtain a complete eradication of the lung lesion.
The management of lung metastases while on Sunitinib
treatmentmust be assessed individually.The target is to reach
the complete eradication of the disease with a multimodal
approach. Unfortunately, currently there are no randomized
trials designed to gain information about the correct timing
of treatment strategy [15]. The data reported in the literature
show that metastasectomy after initial systemic therapy gave
partial or complete response in a majority of patients. In
these patients the median survival was 4.7 years [16]. In
patients with a single resected pulmonarymetastasis a 5 year-
overall survival of 50% has been reported [17]. Moreover,
it must be considered that there is a difference if the lung
metastasis is already present before starting treatment with
Sunitinib or if it appears during therapy. In the second
case a II line pharmacological treatment is indicated, if
metastasectomy is not possible [18]. Regarding the choice
to continue or discontinue the systemic treatment after
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Figure 4: Images show the presence of the nodular lesion in the posterior basal segment of the inferior right lobe ((a) and (b)) and the
pancreatic lesion after the treatment appeared hypodense due to necrotic-colliquative phenomena ((c) and (d)). (a) Axial CECT-Arterial




Figure 5: Images show the absence of local relapses after the surgery in the left kidney (a) and in the lung (b); the hypodense pancreatic lesion
was not more detectable at the pancreatic istm and no other pancreatic lesions were seen (c). (a) CECT-MPR-Coronal Plane. (b) CECT-Axial.
Lung Window. (c) CECT-Axial. Arterial Phase.
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achieving a complete response, in the literature there are some
studies on few patients, so the results are not yet conclusive
[19, 20]. It has been suggested that, after complete response,
there may still be residual cancer cells [19]. Some articles
published in literature affirm that the discontinuation of
chemotherapy may allow the cells to proliferate and lead to
disease recurrence, whereas continuation of chemotherapy
maintains therapeutic pressure on the residual cancer cells,
preventing disease recurrence [20]. Based on these data we
continued treatment after achieving a complete response but,
due to poor tolerance of the patient, we had to stop the
treatment.
However our patient, 47 months after the diagnosis and
20 months after the end of the therapy, is in good con-
dition and disease-free. It is important to remember that
patients with pancreatic metastases from renal cancer could
be symptomatic but also asymptomatic. Considering that
renal clear carcinoma could give metastases even after many
years the remission of the disease, a long time follow-up with
periodic radiological exams should be performed in patients
who had a renal clear carcinoma. Even if the treatment for
pancreatic metastasis from renal clear carcinoma is surgical,
also the medical therapy for the metastatic lesions could be
considered and each case must be assessed individually.
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